Somanetics
This article was originally published in The Gray Sheet
Executive Summary
Initial sales of the firm's first product, the INVOS 3100 cerebral oximeter with the SomaSensor disposable sensor, generated revenues of $570,781 in the second quarter ended May 31; shipments began in "mid-May." The system was cleared by FDA via 510(k) last year ("The Gray Sheet" July 13, 1992, p. 13). The Troy, Michigan firm recorded a loss for the period of $1.6 mil., but predicts that it "could achieve break-even on a monthly basis in our fourth quarter" given "current order backlog and customer demand." Based on a July 1 price hike for the Invos from $10,000 to $13,500 in the U.S. and $15,400 abroad, the company estimates that break-even is "achievable at approximately 80 oximeters per month." The price for the disposable sensors was also raised from approximately $30 to $35.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.